{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:11:04Z","timestamp":1793506264663,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04371-w","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:18:39Z","timestamp":1747325919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mesenchymal stem\/stromal cells as a therapeutic for sepsis: a review on where do we stand?"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-0049","authenticated-orcid":false,"given":"Courtney","family":"Premer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Y.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"4371_CR1","doi-asserted-by":"publisher","unstructured":"Kim MJ, Choi EJ, Choi EJ. Evolving paradigms in sepsis management: a narrative review. Cells. 2024;9(14). https:\/\/doi.org\/10.3390\/cells13141172","DOI":"10.3390\/cells13141172"},{"key":"4371_CR2","doi-asserted-by":"publisher","unstructured":"Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discovery. 2023;9(1):465. https:\/\/doi.org\/10.1038\/s41420-023-01766-7","DOI":"10.1038\/s41420-023-01766-7"},{"key":"4371_CR3","unstructured":"Evans L, Rhodes A, Alhazzani W et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11)."},{"key":"4371_CR4","doi-asserted-by":"publisher","unstructured":"Premer C, Schulman IH, Jackson JS. The role of mesenchymal stem\/stromal cells in the acute clinical setting. Am J Emerg Med. 2021;46:572\u2013578. https:\/\/doi.org\/10.1016\/j.ajem.2020.11.035","DOI":"10.1016\/j.ajem.2020.11.035"},{"key":"4371_CR5","doi-asserted-by":"publisher","unstructured":"Sun X-Y, Ding X-F, Liang H-Y et al. Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies. Stem Cell Res Ther. 2020;11(1):214. https:\/\/doi.org\/10.1186\/s13287-020-01730-7","DOI":"10.1186\/s13287-020-01730-7"},{"issue":"23","key":"4371_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood.V126.23.2220.2220","volume":"126","author":"GM Galstian","year":"2015","unstructured":"Galstian GM, Parovichnikova EN, Makarova PM, et al. The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial). Blood. 2015;126(23):2220. https:\/\/doi.org\/10.1182\/blood.V126.23.2220.2220","journal-title":"Blood"},{"issue":"11","key":"4371_CR7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/stem.2891","volume":"36","author":"D Perlee","year":"2018","unstructured":"Perlee D, van Vught LA, Scicluna BP, et al. Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial. Stem Cells. 2018;36(11):1778\u201388. https:\/\/doi.org\/10.1002\/stem.2891","journal-title":"Stem Cells"},{"key":"4371_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trsl.2018.04.006","volume":"199","author":"X He","year":"2018","unstructured":"He X, Ai S, Guo W, Yang Y, Wang Z, Jiang D, Xu X. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. Translational Res. 2018;199:52\u201361. https:\/\/doi.org\/10.1016\/j.trsl.2018.04.006","journal-title":"Translational Res"},{"key":"4371_CR9","doi-asserted-by":"publisher","unstructured":"McIntyre LA, Stewart DJ, Mei SHJ et al. Cellular Immunotherapy for septic shock. A phase I clinical trial. Am J Respir Crit Care Med. 2017;197(3):337\u2013347. https:\/\/doi.org\/10.1164\/rccm.201705-1006OC","DOI":"10.1164\/rccm.201705-1006OC"},{"issue":"1","key":"4371_CR10","doi-asserted-by":"publisher","first-page":"9222379","DOI":"10.1155\/2022\/9222379","volume":"2022","author":"E Alp","year":"2022","unstructured":"Alp E, Gonen ZB, Gundogan K, et al. The effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock: a promising therapy. Emerg Med Int. 2022;2022(1):9222379. https:\/\/doi.org\/10.1155\/2022\/9222379","journal-title":"Emerg Med Int"},{"key":"4371_CR11","doi-asserted-by":"publisher","unstructured":"Mei SH, Callahan M, dos Santos C. The amethyst (Advanced mesenchymal enhanced cell therapy for septic) trial, dose-escalation phase 1 safety trial of genetically enhanced MSCS (GEM00220) appeared safe and well tolerated in patients with septic shock: a first-in-human. Cytotherapy. 2024;26(6, Supplement):e5. https:\/\/doi.org\/10.1016\/j.jcyt.2024.04.018","DOI":"10.1016\/j.jcyt.2024.04.018"},{"key":"4371_CR12","doi-asserted-by":"publisher","unstructured":"Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation Research. 2011;109(8):923\u2013940. https:\/\/doi.org\/10.1161\/circresaha.111.243147","DOI":"10.1161\/circresaha.111.243147"},{"issue":"2","key":"4371_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4252\/wjsc.v7.i2.368","volume":"26","author":"E Lombardo","year":"2015","unstructured":"Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;26(2):368\u201379. https:\/\/doi.org\/10.4252\/wjsc.v7.i2.368","journal-title":"World J Stem Cells Mar"},{"key":"4371_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3389\/fimmu.2018.01658","volume":"9","author":"L Yan","year":"2018","unstructured":"Yan L, Zheng D, Xu RH. Critical role of tumor necrosis factor signaling in mesenchymal stem cell-based therapy for autoimmune and inflammatory diseases. Front Immunol. 2018;9:1658. https:\/\/doi.org\/10.3389\/fimmu.2018.01658","journal-title":"Front Immunol"},{"key":"4371_CR15","doi-asserted-by":"publisher","unstructured":"Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383\u2013396. https:\/\/doi.org\/10.1038\/nri3209","DOI":"10.1038\/nri3209"},{"key":"4371_CR16","doi-asserted-by":"publisher","unstructured":"Salari V, Mengoni F, Del Gallo F, Bertini G, Fabene PF. The anti-inflammatory properties of mesenchymal stem cells in epilepsy: possible treatments and future perspectives. Int J Mol Sci. 2020;18(24). https:\/\/doi.org\/10.3390\/ijms21249683","DOI":"10.3390\/ijms21249683"},{"key":"4371_CR17","doi-asserted-by":"publisher","unstructured":"Kaundal U, Rakha A. Differential effects of TLR3 and TLR4 activation on MSC-mediated immune regulation. Biochem Biophys Rep. 2024;39:101809. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101809.","DOI":"10.1016\/j.bbrep.2024.101809"},{"key":"4371_CR18","doi-asserted-by":"publisher","unstructured":"Yan L, Zheng D, Xu R-H. Critical role of tumor necrosis factor signaling in mesenchymal stem cell-based therapy for autoimmune and inflammatory diseases. Review. Front Immunol. 2018;9(1658)https:\/\/doi.org\/10.3389\/fimmu.2018.01658","DOI":"10.3389\/fimmu.2018.01658"},{"key":"4371_CR19","doi-asserted-by":"publisher","unstructured":"Kwon HY, Yoon Y, Hong JE, et al. Role of TGF-\u03b2 and p38 MAPK in TSG-6 expression in adipose tissue-derived stem cells in vitro and in vivo. Int J Mol Sci. 2023;29(1). https:\/\/doi.org\/10.3390\/ijms25010477","DOI":"10.3390\/ijms25010477"},{"key":"4371_CR20","doi-asserted-by":"publisher","unstructured":"Zhang N, Utsunomiya T, Lin T et al. Mesenchymal stem cells and NF-\u03baB sensing interleukin-4 over-expressing mesenchymal stem cells are equally effective in mitigating particle-associated chronic inflammatory bone loss in mice. Original research. Front Cell Dev Biology. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.757830","DOI":"10.3389\/fcell.2021.757830"},{"issue":"1","key":"4371_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2567.2010.03281.x","volume":"131","author":"EA Woodward","year":"2010","unstructured":"Woodward EA, Pr\u00eale CM, Nicholson SE, Kolesnik TB, Hart PH. The anti-inflammatory effects of interleukin-4 are not mediated by suppressor of cytokine signalling-1 (SOCS1). Immunol. 2010;131(1):118\u201327. https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03281.x","journal-title":"Immunol Sep"},{"issue":"1","key":"4371_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/critrevimmunol.v32.i1.30","volume":"32","author":"SS Iyer","year":"2012","unstructured":"Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23\u201363. https:\/\/doi.org\/10.1615\/critrevimmunol.v32.i1.30","journal-title":"Crit Rev Immunol"},{"key":"4371_CR23","doi-asserted-by":"publisher","unstructured":"Di G-h, Liu Y, Lu Y, Liu J, Wu C, Duan H-F. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast Cancer cells. PLoS ONE. 2014;9(11):e113572. https:\/\/doi.org\/10.1371\/journal.pone.0113572","DOI":"10.1371\/journal.pone.0113572"},{"issue":"5","key":"4371_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4252\/wjsc.v6.i5.552","volume":"26","author":"D Kyurkchiev","year":"2014","unstructured":"Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells. 2014;26(5):552\u201370. https:\/\/doi.org\/10.4252\/wjsc.v6.i5.552","journal-title":"World J Stem Cells Nov"},{"key":"4371_CR25","doi-asserted-by":"publisher","unstructured":"Gong SC, Yoon Y, Jung PY, Kim MY, Baik SK, Ryu H, Eom YW. Antifibrotic TSG-6 expression is synergistically increased in both cells during coculture of mesenchymal stem cells and macrophages via the JAK\/STAT signaling pathway. Int J Mol Sci. 2022;28(21). https:\/\/doi.org\/10.3390\/ijms232113122","DOI":"10.3390\/ijms232113122"},{"key":"4371_CR26","doi-asserted-by":"publisher","unstructured":"Kuppa SS, Kim HK, Kang JY, Lee SC, Seon JK. Role of mesenchymal stem cells and their paracrine mediators in macrophage polarization: an approach to reduce inflammation in osteoarthritis. Int J Mol Sci. 2022;27(21). https:\/\/doi.org\/10.3390\/ijms232113016","DOI":"10.3390\/ijms232113016"},{"key":"4371_CR27","doi-asserted-by":"publisher","unstructured":"Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther. 2020;11(1):345. https:\/\/doi.org\/10.1186\/s13287-020-01855-9","DOI":"10.1186\/s13287-020-01855-9"},{"key":"4371_CR28","doi-asserted-by":"publisher","unstructured":"Mallis P, Michalopoulos E, Chatzistamatiou T, Giokas CS. Interplay between mesenchymal stromal cells and immune system: clinical applications in immune-related diseases. Explor Immunol. 2021;112\u201339. https:\/\/doi.org\/10.37349\/ei.2021.00010","DOI":"10.37349\/ei.2021.00010"},{"issue":"9","key":"4371_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. https:\/\/doi.org\/10.1038\/nri2395. Nat Rev Immunol 09\/\/print. 2008;8(9):726\u201336.","journal-title":"Nat Rev Immunol 09\/\/print"},{"issue":"9","key":"4371_CR30","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726\u201336. https:\/\/doi.org\/10.1038\/nri2395","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4371_CR31","doi-asserted-by":"publisher","first-page":"e1181","DOI":"10.1002\/cti2.1181","volume":"9","author":"W Li","year":"2020","unstructured":"Li W, Chen W, Huang S, Yao G, Tang X, Sun L. Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3\u2009+\u2009regulatory T cells. Clin Translational Immunol. 2020;9(10):e1181. https:\/\/doi.org\/10.1002\/cti2.1181","journal-title":"Clin Translational Immunol"},{"issue":"6","key":"4371_CR32","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ymthe.2017.04.004","volume":"7","author":"X Zhang","year":"2017","unstructured":"Zhang X, Huang W, Chen X, et al. CXCR5-overexpressing mesenchymal stromal cells exhibit enhanced homing and can decrease contact hypersensitivity. Mol Ther. 2017;7(6):1434\u201347. https:\/\/doi.org\/10.1016\/j.ymthe.2017.04.004","journal-title":"Mol Ther Jun"},{"key":"4371_CR33","doi-asserted-by":"publisher","unstructured":"Castro Ramos A, Widjaja Lomanto MY, Vuong C-K, Ohneda O, Fukushige M. Antibacterial effects of human mesenchymal stem cells and their derivatives: a systematic review. Syst Rev Front Microbiol. 2024;15. https:\/\/doi.org\/10.3389\/fmicb.2024.1430650","DOI":"10.3389\/fmicb.2024.1430650"},{"key":"4371_CR34","doi-asserted-by":"publisher","unstructured":"Chow L, Johnson V, Impastato R, Coy J, Strumpf A, Dow S. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells. Stem Cells Transl Med. 2020;9(2):235\u201349. https:\/\/doi.org\/10.1002\/sctm.19-0092","DOI":"10.1002\/sctm.19-0092"},{"key":"4371_CR35","doi-asserted-by":"publisher","unstructured":"Meisel R, Brockers S, Heseler K et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia. 2011;25(4):648\u201354. https:\/\/doi.org\/10.1038\/leu.2010.310","DOI":"10.1038\/leu.2010.310"},{"key":"4371_CR36","doi-asserted-by":"publisher","unstructured":"Moeinabadi-Bidgoli K, Rezaee M, Rismanchi H, Mohammadi MM, Babajani A. Mesenchymal stem cell-derived antimicrobial peptides as potential anti-neoplastic agents: new insight into anticancer mechanisms of stem cells and exosomes. Review. Front Cell Dev Biology. 2022;10. https:\/\/doi.org\/10.3389\/fcell.2022.900418","DOI":"10.3389\/fcell.2022.900418"},{"issue":"5","key":"4371_CR37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","volume":"11\/14","author":"JM Hare","year":"2017","unstructured":"Hare JM, DiFede DL, Castellanos AM, et al. Randomized comparison of allogeneic vs. Autologous mesenchymal stem cells for non-lschemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69(5):526\u201337. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.009","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"4371_CR38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","volume":"54","author":"JM Hare","year":"2009","unstructured":"Hare JM, Traverse JH, Henry TD, Randomized A, et al. Double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2009.06.055","journal-title":"J Am Coll Cardiol"},{"key":"4371_CR39","doi-asserted-by":"publisher","unstructured":"Wang F, Li Y, Wang B, Li J, Peng Z. The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):31. https:\/\/doi.org\/10.1186\/s13054-022-04287-4","DOI":"10.1186\/s13054-022-04287-4"},{"issue":"7","key":"4371_CR40","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/ccm.0000000000003657","volume":"47","author":"K Schlosser","year":"2019","unstructured":"Schlosser K, Wang J-P, dos Santos C, et al. Effects of mesenchymal stem cell treatment on systemic cytokine levels in a phase 1 dose escalation safety trial of septic shock patients**. Crit Care Med. 2019;47(7):918\u201325. https:\/\/doi.org\/10.1097\/ccm.0000000000003657","journal-title":"Crit Care Med"},{"key":"4371_CR41","unstructured":"Cellular immunotherapy for septic shock (CISS2). A phase II randomized controlled trial. National Library of Medicine (US). 2017. https:\/\/clinicaltrials.gov\/study\/NCT03369275."},{"key":"4371_CR42","unstructured":"Umbilical mesenchymal stromal cells as cellular immunotherapy for septic shock. A multi-center, double blind, phase II randomized controlled trial. National Library of Medicine (US). 2024. https:\/\/clinicaltrials.gov\/study\/NCT05969275"},{"key":"4371_CR43","doi-asserted-by":"publisher","first-page":"154446","DOI":"10.1016\/j.jcrc.2023.154446","volume":"79","author":"PF Laterre","year":"2024","unstructured":"Laterre PF, S\u00e1nchez Garc\u00eda M, van der Poll T, et al. The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: a randomized clinical trial. J Crit Care. 2024;79:154446. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154446","journal-title":"J Crit Care Feb"},{"key":"4371_CR44","doi-asserted-by":"publisher","unstructured":"Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24. https:\/\/doi.org\/10.1186\/s13045-021-01037-x","DOI":"10.1186\/s13045-021-01037-x"},{"issue":"13","key":"4371_CR45","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1016\/j.biomaterials.2014.01.081","volume":"35","author":"CP Ng","year":"2014","unstructured":"Ng CP, Mohamed Sharif AR, Heath DE, et al. Enhanced ex vivo expansion of adult mesenchymal stem cells by fetal mesenchymal stem cell ECM. Biomaterials. 2014;35(13):4046\u201357. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.01.081","journal-title":"Biomaterials 2014\/04\/01\/"},{"key":"4371_CR46","doi-asserted-by":"publisher","unstructured":"Dave C, Mei SHJ, McRae A, et al. Comparison of freshly cultured versus cryopreserved mesenchymal stem cells in animal models of inflammation: a pre-clinical systematic review. Elife. 2022;15(11). https:\/\/doi.org\/10.7554\/eLife.75053","DOI":"10.7554\/eLife.75053"},{"key":"4371_CR47","doi-asserted-by":"publisher","unstructured":"Li C-y, Wu X-y, Tong J-b et al. Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res Ther. 2015;6(1):55. https:\/\/doi.org\/10.1186\/s13287-015-0066-5","DOI":"10.1186\/s13287-015-0066-5"},{"issue":"5","key":"4371_CR48","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","volume":"24","author":"S Kern","year":"2006","unstructured":"Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294\u2013301. https:\/\/doi.org\/10.1634\/stemcells.2005-0342","journal-title":"Stem Cells May"},{"key":"4371_CR49","doi-asserted-by":"publisher","unstructured":"Chen J, Hu C, Chen L et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. 2020;6(10):1153\u20131161. https:\/\/doi.org\/10.1016\/j.eng.2020.02.006","DOI":"10.1016\/j.eng.2020.02.006"},{"issue":"3","key":"4371_CR50","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","volume":"13","author":"D Wang","year":"2018","unstructured":"Wang D, Zhang H, Liang J, et al. A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Rep. 2018;13(3):933\u201341. https:\/\/doi.org\/10.1016\/j.stemcr.2018.01.029","journal-title":"Stem Cell Rep Mar"},{"issue":"1","key":"4371_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13287-024-03891-1","volume":"15","author":"H Lee","year":"2024","unstructured":"Lee H, Cho H-J, Han Y, Lee SH. Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis. Stem Cell Res Ther. 2024;15(1):290. https:\/\/doi.org\/10.1186\/s13287-024-03891-1","journal-title":"Stem Cell Res Ther"},{"key":"4371_CR52","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3389\/fneur.2020.00967","volume":"11","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ. IV\/IT hUC-MSCs infusion in RRMS and NMO: a 10-year follow-up study. Front Neurol. 2020;11:967. https:\/\/doi.org\/10.3389\/fneur.2020.00967","journal-title":"Front Neurol"},{"issue":"11","key":"4371_CR53","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/bioengineering11111160","volume":"11","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Song Y, Zeng Q, Jiang B. Mesenchymal stem cells and their extracellular vesicles are a promising alternative to antibiotics for treating sepsis. Bioengineering. 2024;11(11):1160.","journal-title":"Bioengineering"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04371-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:18:42Z","timestamp":1747325922000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04371-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4371"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04371-w","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"n\/a.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given consent for publication in Stem Cell Research & Therapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMH is the Chief Scientific Officer, a compensated consultant and advisory board member for Longeveron, and holds equity in Longeveron. JMH is also the co-inventor of intellectual property licensed to Longeveron. The University of Miami also stands to gain royalties from the commercialization of the IP. JMH and CPB have a patent for monitoring efficacy of mesenchymal stem cell therapy. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}